David A. Siegel Chemomab Therapeutics Ltd. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.59 - $1.29 $11,623 - $25,413
-19,700 Reduced 52.12%
18,100 $16,000
Q1 2024

May 15, 2024
BUY
$0.5 - $0.86 $1,200 - $2,064
2,400 Added 6.78%
37,800 $29,000
Q4 2023

Feb 14, 2024
BUY
$0.45 - $0.9 $15,930 - $31,860
35,400 New
35,400 $18,000
Q1 2023

May 15, 2023
BUY
$1.44 - $2.94 $16,992 - $34,692
11,800 New
11,800 $18,000

Others Institutions Holding CMMB

# of Institutions
17
Shares Held
4.55M
Call Options Held
0
Put Options Held
0
View Full List

About Chemomab Therapeutics Ltd.

CMMB Quotes by TradingView
  • Ticker CMMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,431,700
  • Market Cap $18.9M
  • Description
  • Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...
More about CMMB
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email